The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker

Current Medical Research and Opinion

Volumn 23, Issue 6, 2007, Pages 1239-1244

  Kuti, Effie L ^a,b   Baker, William L ^a,c   White, C Michael ^a,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

Beta blockers; Calcium channel blockers; Meta analysis; Thiazide diuretics; Type 2 diabetes mellitus

Indexed keywords

AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; METOPROLOL; NIFEDIPINE; PERINDOPRIL; PINDOLOL; TRANDOLAPRIL; VERAPAMIL;

ARTICLE; CLINICAL PRACTICE; COCHRANE LIBRARY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EMBASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIURETICS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 34347204082     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X188044     Document Type: Article

References (15)

1. Mason JM, Dickinson HO, Nicolson DJ, et al. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005;23:1777-81
2. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-9
3. Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006;81:796-806
4. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-24
5. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004;22:1453-8
6. Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6
7. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005;366:895-906
8. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72
9. Hansson L, Hedner T, Lund-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65
10. ALLHAT Collaboration Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
11. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16
12. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10
13. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006;29(Suppl 1):S4-42
14. Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005;28:2261-6
15. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385-9